{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:20:18Z","timestamp":1790911218426,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015883","name":"Sociedad Espa\u00f1ola de Nefrolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ekir.2024.04.022","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T16:11:10Z","timestamp":1713370270000},"page":"2227-2239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ex\u00a0vivo C5b-9 Deposition Test to Monitor Complement Activity in Clinical and Subclinical Atypical Hemolytic Uremic Syndrome and in Transplantation-Associated Thrombotic Microangiopathy"],"prefix":"10.1016","volume":"9","author":[{"given":"Maria","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Llorens-Cebria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Le\u00f3n-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janire","family":"Perurena-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Perez-Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Saumell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina B.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Agraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Sellar\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e0lia","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Moreso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Ariceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Hernandez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conxita","family":"Jacobs-Cach\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.04.022_bib1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.04.022_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3904\/kjim.2019.388","article-title":"Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome","volume":"35","author":"Lee","year":"2020","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.ekir.2024.04.022_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/joim.12546","article-title":"Haemolytic uraemic syndrome","volume":"281","author":"Karpman","year":"2017","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.ekir.2024.04.022_bib4","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","article-title":"HUS and atypical HUS","volume":"129","author":"Jokiranta","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.022_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I-molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.04.022_bib6","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1097\/CCM.0000000000002427","article-title":"The whole is greater than the sum of its parts","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ekir.2024.04.022_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.hoc.2015.02.001","article-title":"Complement: an overview for the clinician","volume":"29","author":"Varela","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ekir.2024.04.022_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2024.04.022_bib9","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.04.022_bib10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.ki.5001581","article-title":"A\u00a0classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders","volume":"70","author":"Besbas","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.04.022_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.04.022_bib12","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.mayocp.2018.07.008","article-title":"Diagnostic utility of complement serology for atypical hemolytic uremic syndrome","volume":"93","author":"Sridharan","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"suppl 11","key":"10.1016\/j.ekir.2024.04.022_bib13","first-page":"2","article-title":"Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis","volume":"14","author":"Laurence","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ekir.2024.04.022_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural basis for eculizumab-mediated inhibition of the complement terminal pathway","volume":"197","author":"Schatz-Jakobsen","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ekir.2024.04.022_bib15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00467-020-04774-2","article-title":"The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab","volume":"36","author":"Tanaka","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.04.022_bib16","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","article-title":"Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults","volume":"6","author":"Barbour","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.04.022_bib17","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.022_bib18","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ckj\/sfab005","article-title":"Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes","volume":"14","author":"Ariceta","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2024.04.022_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.04.022_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","article-title":"Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study","volume":"8","author":"Bouwmeester","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.04.022_bib21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.022_bib22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.04.022_bib23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.04.022_bib24","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.transproceed.2011.02.064","article-title":"Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation-a case report","volume":"43","author":"Chandran","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ekir.2024.04.022_bib25","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/TP.0b013e318230c0bd","article-title":"Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab","volume":"92","author":"Wilson","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.04.022_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.04.022_bib27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","article-title":"Eculizumab and drug-induced haemolytic-uraemic syndrome","volume":"6","author":"Faguer","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2024.04.022_bib28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ekir.2024.04.022_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex\u00a0vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.04.022_bib30","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.022_bib31","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.04.022_bib32","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement activation and thrombotic microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.04.022_bib33","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.022_bib34","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.022_bib35","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","article-title":"Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome","volume":"4","author":"Siedlecki","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.04.022_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.761726","article-title":"Use of eculizumab in pediatric patients with transplant associated thrombotic microangiopathy","volume":"9","author":"Gomez-Ganda","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ekir.2024.04.022_bib37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/ph15070845","article-title":"Complement system as a new target for hematopoietic stem cell transplantation-related thrombotic microangiopathy","volume":"15","author":"Ardissino","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ekir.2024.04.022_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1112257","article-title":"An ex\u00a0vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome","volume":"14","author":"Gastoldi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.04.022_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.04.022_bib40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ekir.2023.10.003","article-title":"Ex\u00a0vivo Test of Complement dysregulation in Atypical hemolytic uremic syndrome Kidney Transplant patients: a Pilot Study","volume":"9","author":"Duineveld","year":"2024","journal-title":"Kidney Int Rep"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924016450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924016450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T09:11:05Z","timestamp":1719997865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924016450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2468024924016450"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.04.022","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ex\u00a0vivo C5b-9 Deposition Test to Monitor Complement Activity in Clinical and Subclinical Atypical Hemolytic Uremic Syndrome and in Transplantation-Associated Thrombotic Microangiopathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}